Leerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE